Advertisement

Lung

, Volume 168, Supplement 1, pp 230–239 | Cite as

A placebo-controlled blinded comparison of nedocromil sodium and beclomethasone dipropionate in bronchial asthma

  • K. -Ch. Bergmann
  • C. P. Bauer
  • A. Overlack
The Role Of Inflammatory Processes In Airway Hyperresponsiveness: Implications For Treatment

Abstract

Two hundred and two patients aged 12–78 with chiefly moderate to severe asthma took part in a multicenter randomized blined group comparison of nedocromil sodium (NS) 4 mg four times daily, beclomethasone dipropionate (BD) 0.1 mg four times daily, and placebo. Patients were assessed at the start and end of a two week baseline and after three and six weeks of treatment.

Compared with placebo, both NS and BD significantly improved day-time dyspnoea and day and nighttime cough, as assessed by diary card scores. Lung function (FEV1) was significantly improved in the BD group. In the NS group there was also a significant reduction in concomitant use of inhaledβ 2-agonists. Overall opinions of efficacy by clinicians and patients were significantly in favor of both active treatments over placebo. There were no significant differences between the three treatments for peak expiratory flow rates, morning tightness or nighttime dyspnoea. Comparison between the two active treatments showed no significant differences in any of the variables.

Key words

Asthma Multicenter randomized blinded group comparison Nedocromil sodium Beclomethasone dipropionate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Editorial (1986) Bronchial asthma and the environment. Lancet ii:786–787Google Scholar
  2. 2.
    Charlton JRH, Velez R (1983) Some international comparisons of mortality amenable to medical intervention. Br Med J 292:295–301CrossRefGoogle Scholar
  3. 3.
    Hay IFC, Higgenbottam TW (1987) Has the management of asthma improved? Lancet ii:609–611CrossRefGoogle Scholar
  4. 4.
    Lal S, Malhotra S, Gribben D, Hodder D (1984) Nedocromil sodium, a new drug for the management of bronchial asthma. Thorax 39:809–812PubMedCrossRefGoogle Scholar
  5. 5.
    Chatterjee PC, Fyans PG, Chatterjee SS (1986) A trial comparing nedocromil sodium (Tilade) and placebo in the management of perennial bronchial asthma. Eur J Respir Dis 69(Suppl. 147):314–316Google Scholar
  6. 6.
    Williams AJ, Stableforth D (1986) The addition of nedocromil sodium to maintenance therapy in the management of patients with bronchial asthma. Eur J Respir Dis 69(Suppl. 147):340–343Google Scholar
  7. 7.
    Wells E, Jackson CG, Harper ST, Mann J, Eady RP (1986) Characterization of primate bronchoalveolar mast cells. II. Inhibition of histamine, LTC4, and PGD2 release from primate bronchoalveolar mast cells and a comparison with rat peritoneal mast cells. J Immunol 137:3941–3945PubMedGoogle Scholar
  8. 8.
    Moqbel R, Cromwell O, Walsh GM, Wardlaw AJ, Kurlak L, Kay AB (1988) Effect of nedocromil sodium (Tilade) on the activation of human eosinophils and neutrophils and the release of histamine from mast cells. Allergy 43:268–276PubMedCrossRefGoogle Scholar
  9. 9.
    Thorel T, Joseph M, Tsicopoulos A, Tonnel AB, Capron A (1988) Inhibition by nedocromil sodium of IgE-mediated activation of human mononuclear phagocytes and platelets in allergy. Int Arch Allergy Appl Immunol 85:232–237PubMedGoogle Scholar
  10. 10.
    Thorel T, Joseph M, Vorng H, Capron A (1988) Regulation of IgE-dependent antiparasite functions of rat macrophages and platelets by nedocromil sodium. Int Arch Allergy Appl Immunol 85:227–231PubMedGoogle Scholar
  11. 11.
    Mack GA, Skillings JH (1980) A Friedman-type rank test for main effects in a two-factor ANOVA. J Am Sci Assoc 75Google Scholar
  12. 12.
    Postma DS, Gimeno F, Van der Weile LTH, Sluiter HJ (1985) Assessment of ventilatory variables in survival prediction of patients with chronic airflow obstruction: the importance of reversibility. Eur J Respir Dis 67:360–368PubMedGoogle Scholar
  13. 13.
    Postma DS, De Vries K, Koeter GH, Gluiter HJ (1986) Independent influence of reversibility of airflow obstruction and non-specific hyperreactivity on the long-term course of lung function in chronic airflow obstruction. Am Rev Respir Dis 134:276–280PubMedGoogle Scholar
  14. 14.
    James PNE, Anderson JB, Prior JG, White JP, Henry JA, Cochrane GM (1985) Patterns of drug taking in patients with chronic airflow obstruction. Postgrad Med J 61:7–10PubMedCrossRefGoogle Scholar
  15. 15.
    Spector SL (1985) Is your asthmatic patient really complying? Ann Allergy 55:552–556PubMedGoogle Scholar
  16. 16.
    Carrasco E, Sepulveda R (1986) The acceptability, tolerability and safety of nedocromil sodium in long-term clinical use Eur J Respir Dis 69(Suppl. 147):311–313Google Scholar
  17. 17.
    Lal S, Malhotra S, Gribben D, Hodder D (1986) An open assessment study of the acceptability, tolerability and safety of nedocromil sodium in long-term clinical use in patients with bronchial asthma. Eur J Respir Dis 69(Suppl. 147):136–142Google Scholar
  18. 18.
    Gonzalez JP, Brodgen RN (1987) Nedocromil sodium: a preliminary report of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of reversible obstructive airways disease. Drugs 34:560–577PubMedCrossRefGoogle Scholar
  19. 19.
    Goldstein DE, Konig P (1983) Effect of inhaled beclomethasone dipropionate on hypothalamic-pituitary-adrenal axis function in children with asthma. Pediatrics 72:60–64PubMedGoogle Scholar
  20. 20.
    Yernault JC, Leclercq R, Schanderyl W, Virasoro E, De Coster A, Copinschi G (1977) The endocrinometabolic effects of beclomethasone dipropionate in asthmatic patients. Chest 71:698–702PubMedCrossRefGoogle Scholar
  21. 21.
    Gaddie J, Reid LW, Skinner C, Petrie GR, Sinclair DJM, Palmer KNV (1973) Aerosol beclomethasone dipropionate: a dose-response study in chronic bronchial asthma. Lancet ii:280–281CrossRefGoogle Scholar
  22. 22.
    Costello JF, Clark TJH (1974) Response of patients receiving high-dose beclomethasone dipropionate. Thorax 29:571–573PubMedCrossRefGoogle Scholar
  23. 23.
    Toogood JH, Lefcoe NM, Haines DSM, Jennings B, Errington N, Baksh L, Chuang L (1977) A graded dose assessment of the efficacy of beclomethasone dipropionate aerosol for severe chronic asthma. J Allergy Clin Immunol 59:298–308PubMedCrossRefGoogle Scholar
  24. 24.
    Nassif E, Weinberger M, Sherman B, Brown K (1987) Extrapulmonary effects of maintenance corticosteroid therapy with alternate-day prednisone and inhaled beclomethasone in children with chronic asthma. J Allergy Clin Immunol 80:518–529PubMedCrossRefGoogle Scholar
  25. 25.
    Hollman GA, Allen DB (1988) Overt glucocorticoid excess due to inhaled corticosteroid therapy. Pediatrics 81:452–455PubMedGoogle Scholar
  26. 26.
    Kruszynska YT, Greenstone M, Home PD, Cooke NJ (1987) Effect of high dose inhaled beclomethasone dipropionate on carbohydrate and lipid metabolism in normal subjects. Thorax 42:881–884PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 1990

Authors and Affiliations

  • K. -Ch. Bergmann
    • 1
  • C. P. Bauer
    • 2
  • A. Overlack
    • 3
  1. 1.Allergie- und Asthma-KlinikBad LippspringeFRG
  2. 2.Kinder- und Poliklinik der TU MünchenMünchen
  3. 3.Medizinische Universitäts- und PolikinikBonnFederal Republic of Germany

Personalised recommendations